FC131 TFA

Overview

FC131 TFA is a CXCR4 antagonist that inhibits AKT kinase activity in AML OCI-AML3 cells. D-ArgFC131, a derivative of FC131 TFA, inhibits the phosphorylation of downstream ERK1/2 and Akt , induces caspase-3 pathway-mediated apoptosis , and causes cell cycle arrest. FC131 TFA exerts cytotoxic effects in cancer cells such as AML cells. FC131 TFA is applicable for cancer-related research.

Application

Products | Products > Peptides | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Cancer | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CXCR | Products > Signaling Pathways > Akt | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-P1104A
• CAS No.: 842166-42-1
• Molecular Formula: C38H48F3N11O8
• Molecular Weight: 843.85
• Purity: 99.87%
• Storage: Sealed storage, away from moisture. Powder -80°C, 2 years , -20°C, 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.08 mg/mL (2.46 mM); Clear solution
• Availability: In-stock

Source

Original product source